Results 81 to 90 of about 32,142 (226)
Molecular and Hematological Characterization of α-Thalassemia in Denizli Province
Acta Haematologica Oncologica TurcicaAim: Alpha thalassemia, a common monogenic disorder, occurs with defective synthesis of the α-globin chain and has a very wide clinical spectrum depending on the disorders in the globin genes.
Derya Karaer +3 more
doaj +1 more source
Multitest Screening in Hematology [PDF]
, 1973 The concept of multitest screening for hematological disorders is not necessarily a new one. Implementation of such ideas has recently become possible, for the automated electronic instruments performing sequential multiple analyses within very short ...
Johnston, Charles L., Jr.
core +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.ABSTRACT Hemoglobinopathies are prevalent globally; diagnosis is complex in high genetic admixture populations like Brazil. We report, in two pediatric siblings, the first documented cases in Brazil of heterozygosity for hemoglobin (Hb) O‐Arab with coinheritance of α‐thalassemia (αα/−α4.2; −α3.7/−α4.2), resulting in microcytic and hypochromic anemia ...
Elisângela de Souza Miranda Muynarsk +9 more
wiley +1 more source
A rare case of alpha-thalassaemia intermedia in a Malay patient double heterozygous for α+ –thalassaemia and a mutation in α1 globin gene CD59 (GGC → GAC) [PDF]
, 2009 A rare case of thalassaemia-intermedia involving a non-deletion alpha thalassemia point mutation in the α1-globin gene CD59 (GGC → GAC) and a deletion α+ (-α3.7) thalassaemia in which use of high performance liquid chromatography (HPLC) C-gram Hb subtype
A. S., Nor Azian +4 more
core
Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell +14 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 4, Page 718-727, April 2026.ABSTRACT Sickle cell disease (SCD) is a chronic inflammatory state, characterized by increased plasma values of inflammatory and angiogenic proteins. Although red blood cell (RBC) transfusion is known to have immunomodulatory effects in other conditions, its potential effects on the inflammatory state in SCD remain largely unknown.
Lydian A. de Ligt +9 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue S1, Page 5-16, April 2026.What are the available data on incidence & prevalence prognosis risk factors of severity of sickle cell disease in sub‐Saharan Africa? ABSTRACT Sickle Cell Disease (SCD) is highly prevalent in sub‐Saharan Africa. Epidemiological data remain sparse, but regional screening and research initiatives are expanding.
Brigitte Ranque +2 more
wiley +1 more source
Genetics and Genomics in Sickle Cell Disease in Africa
American Journal of Hematology, Volume 101, Issue S1, Page 47-55, April 2026.ABSTRACT Advanced genomic technologies are revolutionizing our ability to understand complex diseases. Large‐scale population studies are needed to realize the potential of using individual genetic information to personalize treatments for better patient outcomes for chronic non‐communicable diseases, such as sickle cell disease (SCD).
Siana Nkya +2 more
wiley +1 more source
Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview
American Journal of Hematology, Volume 101, Issue S1, Page 56-74, April 2026.ABSTRACT The practical aspects of developing curative treatments for sickle cell disease (SCD) in Africa, such as gene therapy and hematopoietic stem cell transplantation, involve strengthening healthcare infrastructure, training healthcare professionals, establishing regional treatment centers, and creating national SCD programs.
Adetola A. Kassim +2 more
wiley +1 more source